(P046) Prediction of Pathologic Complete Response After Neoadjuvant Chemoradiation Therapy for Rectal Cancer Using Radiographic Texture Analysis

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Several radiographic texture features from the pre-RT CT scan were identified as potential predictors of pCR in rectal cancer patients after neoadjuvant chemoradiation therapy. Future work will focus on validating these features in a larger dataset.

Martin T. King, MD, PhD, William F. Sensakovic, PhD, Albert Koong, MD, PhD, Daniel T. Chang, MD; Stanford Cancer Institute; Florida Hospital

PURPOSE: To determine if certain radiographic texture features from pre–radiation therapy (pre-RT) computed tomography (CT) scans can predict pathologic complete response (pCR) after neoadjuvant chemoradiation therapy for rectal cancer.

METHODS: We conducted an institutional review board (IRB)-approved retrospective analysis of 30 patients with rectal cancer who received neoadjuvant chemoradiation therapy, followed by total mesorectal excision, between 2009 and 2012. We collected relevant demographic, staging, and treatment-related information from the electronic medical records. We also downloaded treatment planning CT scans and structure sets onto a specialized computerized workstation. Gross tumor volumes (GTVs) of the primary rectal lesion were adjusted, if necessary, based on careful review of the pre-RT non–contrast-enhanced CT and positron emission tomography (PET) data. GTV voxels corresponding to air, defined as less than −50 Hounsfield units (HU), were excluded. Multiresolution texture analysis was performed by passing CT scans through a three-dimensional spatial bandpass (Laplacian of Gaussian) filter using sigma values of 1.0 mm, 2.0 mm, and 3.0 mm in order to enhance textural features at fine, medium, and coarse scales, respectively. Mean texture feature values within the GTV for entropy, uniformity, kurtosis, skewness, and standard deviation were then calculated. The performance of each feature in predicting pCR was evaluated using receiver operating characteristic (ROC) analysis. Then, 95% confidence intervals (CIs) for area under the curve (AUC) values were estimated using a bootstrapping method with 2,000 iterations. Features with an AUC above a 0.75 threshold were identified as potential predictors of pCR.

RESULTS: Treatment planning PET scans were available for 29 of 30 patients. Six patients achieved a pCR at the time of surgery. Kurtosis demonstrated AUC values above the 0.75 threshold for fine (0.78; 95% CI, 0.46–0.89), medium (0.77; 95% CI, 0.48–0.91), and coarse (0.74; 95% CI, 0.38–0.87) scales. Skewness also exhibited AUC values above the 0.75 threshold for fine (0.77; 95% CI, 0.49–0.89), medium (0.79; 95% CI, 0.51–0.90), and coarse (0.78; 95% CI, 0.51–0.90) scales. Skewness on the medium scale allowed for a sensitivity of 66.3% at a specificity of 80.1% for predicting pCR.

CONCLUSION: Several radiographic texture features from the pre-RT CT scan were identified as potential predictors of pCR in rectal cancer patients after neoadjuvant chemoradiation therapy. Future work will focus on validating these features in a larger dataset.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content